A Multicenter, Randomized, Open-labeled, Cross-over, Active-controlled, Phase IV Clinical Trial to Evaluate the Preference of Formulation and the Efficacy and Safety of Renamezin and Kremezin in Pre-dialysis Patients With Chronic Renal Failure

PHASE4CompletedINTERVENTIONAL
Enrollment

153

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Chronic Renal Failure
Interventions
DRUG

Renamezin capsule

DRUG

Kremezin granule

Trial Locations (1)

03722

Sevrance Hospital of Yonsei University, Seoul

All Listed Sponsors
lead

Daewon Pharmaceutical Co., Ltd.

INDUSTRY